Clinical research

Clinical analysis of Kaposi form hemangioendothelioma in 19 children

  • Jin-jun CAO ,
  • Wei XIE ,
  • Xiao-dong ZHU ,
  • Hao XIA
Expand
  • Department of Pediatric Emergency and Critical Care Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2020-07-13

  Online published: 2021-05-14

Abstract

Objective

· To assess the clinical characteristics and treatment strategies of Kaposi form hemangioendothelioma (KHE) in children.

Methods

· The retrospective study was carried out on 19 cases of children diagnosed with KHE from January 2009 to December 2017 in Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.The general demographics, tumor characteristics, presence or absence of Kasabach-Merritt phenomenon (KMP), treatment and outcome were statistically analyzed. The difference between the children with KMP and without KMP were compared in whether the tumor involved the skin and the deep muscles.

Results

· Of the 19 children with KHE, 13 (68.4%) were male and 6 (31.6%) were female; 17 children (89.5%) presented within the first year of life and 12 children (63.2%) were detected at birth; 6 cases occurred on head and neck, 4 cases in the trunk, 9 cases in the extremities, and none was multifocal.Seven cases (36.8%) were complicated with KMP after onset. There was no significant difference in cutaneous lesions (P=0.617), while there was a significant difference in deep muscles involvement (P=0.017) between the cases complicated with KMP and without KMP. All cases were diagnosed on the basis of histopathology and immunohistochemistry after operation, in which 8 were completely removed, 5 were partially excised, and 6 were performed biopsy. All the tumors were substantial and aggressive growth. Seven children were treated by propranolol before operation but no obvious effect was found. Ten children were given oral corticosteroids, and five of them were found tumor shrinking and underwent operation. The treatment of corticosteroids resulted in higher effect than that of propranolol (P=0.044). Two children who showed resistance to corticosteroids accepted a combination therapy of corticosteroids and vincristine, and the tumor shrank at last. During the follow-up of 2 to 5 years, the cases which performed complete resection were without recurrence, and those who accepted partial excision also survived with postoperative corticosteroids treatment.

Conclusion

· Most KHE cases occur in infancy. The cases might be predisposed with KPM when the tumors involve the deep muscles. The children with typical clinical features should undergo operation as soon as possible. Besides, those with atypical characters should take biopsy to achieve definite diagnosis. The cases with KMP or with giant tumors that are impossible to be removed could be given corticosteroids treatment with or without vincristine. Although propranolol showed a poor curative effect, it could be used for a diagnostic treatment.

Cite this article

Jin-jun CAO , Wei XIE , Xiao-dong ZHU , Hao XIA . Clinical analysis of Kaposi form hemangioendothelioma in 19 children[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(4) : 514 -518 . DOI: 10.3969/j.issn.1674-8115.2021.04.016

References

1 Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis[J]. Am J Surg Pathol, 1993, 17(4): 321-328.
2 Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals[J]. J Pediatr, 2013, 162(1): 142-147.
3 Kelly M. Kasabach-Merritt phenomenon[J]. Pediatr Clin North Am, 2010, 57(5): 1085-1089.
4 李冰, 张茜, 赵志华, 等. 新生儿卡波西型血管内皮瘤伴K-M现象一例[J]. 中华儿科杂志, 2015, 53(2): 144-145.
5 高鹏飞, 舒曼, 谢钧韬, 等. 卡波西型血管内皮瘤13例临床分析[J]. 中华实用儿科临床杂志, 2017, 32(11): 841-844.
6 Drolet BA, Trenor CC, Brand?o LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma[J]. J Pediatr, 2013, 163(1): 285-291.
7 Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon[J]. Br J Dermatol, 2018, 179(2): 457-463.
8 Dasgupta R, Fishman SJ. ISSVA classification[J]. Semin Pediatr Surg, 2014, 23(4): 158-161.
9 Nakaya T, Morita K, Kurata A, et al. Multifocal Kaposiform hemangioendothelioma in multiple visceral organs: an autopsy of 9-day-old female baby[J]. Hum Pathol, 2014, 45(8): 1773-1777.
10 Ryu YJ, Choi YH, Cheon JE, et al. Imaging findings of Kaposiform hemangioendothelioma in children[J]. Eur J Radiol, 2017, 86: 198-205.
11 Fernández Y, Bernabeu-Wittel M, García-Morillo JS. Kaposiform hemangioendothelioma[J]. Eur J Intern Med, 2009, 20(2):106-113.
12 Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon[J]. J Am Acad Dermatol, 2005, 52(4): 616-622.
13 Duan L, Renzi S, Weidman D, et al. Sirolimustreatment of an infant with intrathoracic Kaposiform hemangioendothelioma complicated by life-threatening pleural and pericardial effusions[J]. J Pediatr Hematol Oncol, 2020, 42(1): 74-78.
14 Tlougan BE, Lee MT, Drolet BA, et al. Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey[J]. J Pediatr Hematol Oncol, 2013, 35(8): 618-622.
15 Chiu YE, Drolet BA, Blei F, et al. Variable response to propranolol treatment of Kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon[J]. Pediatr Blood Cancer, 2012, 59(5): 934-938.
16 Filippi L, Tamburini A, Berti E, et al. Successful propranolol treatment of a Kaposiform hemangioendothelioma apparently resistant to propranolol[J]. Pediatr Blood Cancer, 2016, 63(7): 1290-1292.
17 Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from Kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery[J]. Int J Clin Oncol, 2012, 17(5): 512-516.
18 Liu XH, Li JY, Qu XH, et al. Clinical outcomes for systemic corticosteroids versus vincristine in treating Kaposiform hemangioendothelioma and tufted angioma[J]. Medicine (Baltimore), 2016, 95(20): e3431.
19 Ji Y, Chen SY, Xiang B, et al. Sirolimus for the treatment of progressive Kaposiform hemangioendothelioma: a multicenter retrospective study[J]. Int J Cancer, 2017, 141(4): 848-855.
20 George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas[J]. Arch Dermatol, 2004, 140(8): 963-969.
21 Fahrtash F, McCahon E, Arbuckle S. Successful treatment of Kaposiform hemangioendothelioma and tufted angioma with vincristine[J]. J Pediatr Hematol Oncol, 2010, 32(6): 506-510.
22 Peng SH, Yang KY, Xu ZC, et al. Vincristine and sirolimus in the treatment of Kaposiform haemangioendothelioma[J]. J Paediatr Child Health, 2019, 55(9): 1119-1124.
23 Hartman KR, Moncur JT, Minniti CP, et al. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon [J]. J Pediatr Hematol, 2009, 31(9): 690-692.
24 Wang Z, Yao W, Sun H, et al. Sirolimus therapy for Kaposiform hemangioendothelioma with long-term follow-up[J]. J Dermatol, 2019, 46(11): 956-961.
25 Malhotra Y, Yang CS, McNamara J, et al. Congenital Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon successfully treated with low-dose radiation therapy[J]. Pediatr Dermatol, 2014, 31(5): 595-598.
26 Wang P, Zhou W, Tao L, et al. Clinical analysis of Kasabach-Merritt syndrome in 17 neonates[J]. BMC Pediatr, 2014, 14: 146.
27 Schaefer BA, Wang DH, Merrow AC, et al. Long-term outcome for Kaposiform hemangioendothelioma: a report of two cases[J]. Pediatr Blood Cancer, 2017, 64(2): 284-286.
Outlines

/